Skip to main content
Top
Published in: Journal of Cardiothoracic Surgery 1/2016

Open Access 01-12-2016 | Research article

Evaluation of new classifications of N descriptor in non-small cell lung cancer (NSCLC) based on the number and the ratio of metastatic lymph nodes

Authors: Konrad Pawełczyk, Marek Marciniak, Piotr Błasiak

Published in: Journal of Cardiothoracic Surgery | Issue 1/2016

Login to get access

Abstract

Background

The aim of the study was to evaluate the prognostic power of new classifications of N descriptor created basing on the number (NLN) and the ratio of metastatic lymph nodes (RLN) in NSCLC compared to the current classification (CLN).

Methods

The data of 529 patients with NSCLC operated with the intention of radical resection, were analyzed. The new categories of N descriptor were created as follows: 1) NLN - median number of metastatic nodes was 3, thus in NLN0 the number of metastatic nodes =0, in NLN1 1-2, in NLN2 ≥ 3, 2) RLN - median ratio (number of metastatic lymph nodes to all nodes removed) was 12.4 %, thus in RLN0 the ratio was 0, in RLN1 < 13 %, in RLN2 > 13 %. The prognostic value of each classification was calculated on the basis of hazard ratios defined in multivariate Cox proportional hazard model.

Results

The new classifications of N descriptor turned out to be an independent strong prognostic factor (p <0.001) with a 5-year survival rate NLN0-62 %, NLN1-39 %, NLN2-26 % and RLN0-62 %, RLN1-37 % and RLN2-26 %. For 5-year survival rates in CLN0-62 %, CLN1-42 %, CLN2-24 % (p < 0.001), a higher prognostic value of new classifications was not demonstrated, the hazard ratio amounted to 2.22, 2.08, 2.49 for NLN2, RLN2 and CLN2 respectively.

Conclusion

Despite the significantly high prognostic power, the new classifications cannot be considered superior over CLN. There are some deficiencies in the current classification, therefore further studies on its improvement are needed.
Literature
1.
go back to reference International Union Against Cancer (UICC). In: Hermanek P, Sobin LH, editors. TNM Classification of malignant tumours. 4th ed. Berlin, Heidelberg, New York: Springer Verlag; 1987. International Union Against Cancer (UICC). In: Hermanek P, Sobin LH, editors. TNM Classification of malignant tumours. 4th ed. Berlin, Heidelberg, New York: Springer Verlag; 1987.
2.
go back to reference Lorent N, De Leyn P, Lievens Y, Verbeken E, Nackaerts K, Dooms C, et al. Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancertreated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol. 2004;15:1645–53.CrossRefPubMed Lorent N, De Leyn P, Lievens Y, Verbeken E, Nackaerts K, Dooms C, et al. Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancertreated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol. 2004;15:1645–53.CrossRefPubMed
3.
go back to reference Detterbeck F. What to do with “Surprise” N2?: intraoperative management of patients with non-small cell lung cancer. J Thorac Oncol. 2008;3:289–302.CrossRefPubMed Detterbeck F. What to do with “Surprise” N2?: intraoperative management of patients with non-small cell lung cancer. J Thorac Oncol. 2008;3:289–302.CrossRefPubMed
4.
go back to reference Decaluwe H, De Leyn P, Vansteenkiste J, Dooms C, Van Raemdonck D, Nafteux P, et al. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg. 2009;36:433–9.CrossRefPubMed Decaluwe H, De Leyn P, Vansteenkiste J, Dooms C, Van Raemdonck D, Nafteux P, et al. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg. 2009;36:433–9.CrossRefPubMed
5.
go back to reference Riquet M, Assouad J, Bagan P, Foucault C, Le Pimpec BF, et al. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis. Ann Thorac Surg. 2005;79:225–33.CrossRefPubMed Riquet M, Assouad J, Bagan P, Foucault C, Le Pimpec BF, et al. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis. Ann Thorac Surg. 2005;79:225–33.CrossRefPubMed
6.
go back to reference Sobin LH, Gospodarowicz M, Wittekind C, editors. UICC TNM Classification of malignant tumours. 7th ed. New York: Wiley-Liss; 2009. Sobin LH, Gospodarowicz M, Wittekind C, editors. UICC TNM Classification of malignant tumours. 7th ed. New York: Wiley-Liss; 2009.
7.
go back to reference Vinh-Hung V, Verschraegen C, Promish DI, Cserni G, Van de Steene J, Tai P, et al. Ratios of involved nodes in early breast cancer. Breast Cancer Res. 2004;6:R680–8.CrossRefPubMedPubMedCentral Vinh-Hung V, Verschraegen C, Promish DI, Cserni G, Van de Steene J, Tai P, et al. Ratios of involved nodes in early breast cancer. Breast Cancer Res. 2004;6:R680–8.CrossRefPubMedPubMedCentral
8.
go back to reference Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol. 2003;169:943–5.CrossRefPubMed Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol. 2003;169:943–5.CrossRefPubMed
9.
go back to reference Peschaud F, Benoist S, Julié C, Beauchet A, Penna C, Rougier P, et al. The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer. Ann Surg. 2008;248:1067–73.CrossRefPubMed Peschaud F, Benoist S, Julié C, Beauchet A, Penna C, Rougier P, et al. The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer. Ann Surg. 2008;248:1067–73.CrossRefPubMed
10.
go back to reference De Leyn P, Lardinois D, Van Schil P, Rami-Porta R, Passlick B, Zielinski M, et al. European trends in preoperative and intraoperative nodal staging: ESTS guidelines. J Thorac Oncol. 2007;2:357–61.CrossRefPubMed De Leyn P, Lardinois D, Van Schil P, Rami-Porta R, Passlick B, Zielinski M, et al. European trends in preoperative and intraoperative nodal staging: ESTS guidelines. J Thorac Oncol. 2007;2:357–61.CrossRefPubMed
11.
go back to reference Osarogiagbon RU. Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM. J Thorac Dis. 2012;4:214–6.PubMedPubMedCentral Osarogiagbon RU. Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM. J Thorac Dis. 2012;4:214–6.PubMedPubMedCentral
12.
go back to reference Cho HJ, Kim SR, Kim HR, Han JO, Kim YH, Kim DK, et al. Modern outcome and risk analysis of surgically resected occult N2 non-small cell lung cancer. Ann Thorac Surg. 2014;97:1920–5.CrossRefPubMed Cho HJ, Kim SR, Kim HR, Han JO, Kim YH, Kim DK, et al. Modern outcome and risk analysis of surgically resected occult N2 non-small cell lung cancer. Ann Thorac Surg. 2014;97:1920–5.CrossRefPubMed
13.
go back to reference Cerfolio RJ, Bryant AS, Ojha B, Eloubeidi M. Improving the inaccuracies of clinical staging of patients with NSCLC: a prospective trial. Ann Thorac Surg. 2005;80:1207–13.CrossRefPubMed Cerfolio RJ, Bryant AS, Ojha B, Eloubeidi M. Improving the inaccuracies of clinical staging of patients with NSCLC: a prospective trial. Ann Thorac Surg. 2005;80:1207–13.CrossRefPubMed
14.
go back to reference Van Meerbeeck JP, Surmont VF. Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments. Lung Cancer. 2009;65:257–67.CrossRefPubMed Van Meerbeeck JP, Surmont VF. Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments. Lung Cancer. 2009;65:257–67.CrossRefPubMed
15.
go back to reference Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI, et al. Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective American College of Surgeons Oncology Group Z0030 trial. Chest. 2011;139:1124–9.CrossRefPubMedPubMedCentral Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI, et al. Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective American College of Surgeons Oncology Group Z0030 trial. Chest. 2011;139:1124–9.CrossRefPubMedPubMedCentral
16.
go back to reference Vielva LR, Jaen MW, Alcácer JA, Cardona MC. State of the art in surgery for early stage NSCLC-does the number of resected lymph nodes matter? Transl Lung Cancer Res. 2014;3:95–9.PubMedPubMedCentral Vielva LR, Jaen MW, Alcácer JA, Cardona MC. State of the art in surgery for early stage NSCLC-does the number of resected lymph nodes matter? Transl Lung Cancer Res. 2014;3:95–9.PubMedPubMedCentral
17.
go back to reference Ludwig MS, Goodman M, Miller DL, Johnstone PA. Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer. Chest. 2005;128:1545–50.CrossRefPubMed Ludwig MS, Goodman M, Miller DL, Johnstone PA. Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer. Chest. 2005;128:1545–50.CrossRefPubMed
18.
go back to reference Doddoli C, Aragon A, Barlesi F, Chetaille B, Robitail S, Giudicelli R, et al. Does the extent of lymph node dissection influence outcome in patients with stage I non-small-cell lung cancer? Eur J Cardiothorac Surg. 2005;27:680–5.CrossRefPubMed Doddoli C, Aragon A, Barlesi F, Chetaille B, Robitail S, Giudicelli R, et al. Does the extent of lymph node dissection influence outcome in patients with stage I non-small-cell lung cancer? Eur J Cardiothorac Surg. 2005;27:680–5.CrossRefPubMed
19.
go back to reference Wu YC, Lin CF, Hsu WH, Huang BS, Huang MH, Wang LS. Long-term results of pathological stage I non-small cell lung cancer: validation of using the number of totally removed lymph nodes as a staging control. Eur J Cardiothorac Surg. 2003;24:994–1001.CrossRefPubMed Wu YC, Lin CF, Hsu WH, Huang BS, Huang MH, Wang LS. Long-term results of pathological stage I non-small cell lung cancer: validation of using the number of totally removed lymph nodes as a staging control. Eur J Cardiothorac Surg. 2003;24:994–1001.CrossRefPubMed
20.
go back to reference Nwogu CE, Groman A, Fahey D, Yendamuri S, Dexter E, Demmy TL, et al. Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer. Ann Thorac Surg. 2012;93:1614–9.CrossRefPubMed Nwogu CE, Groman A, Fahey D, Yendamuri S, Dexter E, Demmy TL, et al. Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer. Ann Thorac Surg. 2012;93:1614–9.CrossRefPubMed
21.
go back to reference Fukui T, Mori S, Yokoi K, Mitsudomi T. Significance of the number of positive lymph nodes in resected non-small cell lung cancer. J Thorac Oncol. 2006;1:120–5.CrossRefPubMed Fukui T, Mori S, Yokoi K, Mitsudomi T. Significance of the number of positive lymph nodes in resected non-small cell lung cancer. J Thorac Oncol. 2006;1:120–5.CrossRefPubMed
22.
go back to reference Matsuguma H, Oki I, Nakahara R, Ohata N, Igarashi S, Mori K, et al. Proposal of new nodal classifications for non-small-cell lung cancer based on the number and ratio of metastatic lymph nodes. Eur J Cardiothorac Surg. 2012;41:19–24.PubMedPubMedCentral Matsuguma H, Oki I, Nakahara R, Ohata N, Igarashi S, Mori K, et al. Proposal of new nodal classifications for non-small-cell lung cancer based on the number and ratio of metastatic lymph nodes. Eur J Cardiothorac Surg. 2012;41:19–24.PubMedPubMedCentral
23.
go back to reference Lee JG, Lee CY, Park IK, Kim DJ, Park SY, Kim KD, et al. Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival. Ann Thorac Surg. 2008;85:211–5.CrossRefPubMed Lee JG, Lee CY, Park IK, Kim DJ, Park SY, Kim KD, et al. Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival. Ann Thorac Surg. 2008;85:211–5.CrossRefPubMed
24.
go back to reference Osarogiagbon RU, Allen JW, Farooq A, Berry A, O’Brien T. Pathologic lymph node staging practice and stage-predicted survival after resection of lung cancer. Ann Thorac Surg. 2011;91:1486–92.CrossRefPubMed Osarogiagbon RU, Allen JW, Farooq A, Berry A, O’Brien T. Pathologic lymph node staging practice and stage-predicted survival after resection of lung cancer. Ann Thorac Surg. 2011;91:1486–92.CrossRefPubMed
25.
go back to reference Nordgård O, Singh G, Solberg S, Jørgensen L, Halvorsen AR, Smaaland R, et al. Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer. PLoS One. 2013;8:e62153.CrossRefPubMedPubMedCentral Nordgård O, Singh G, Solberg S, Jørgensen L, Halvorsen AR, Smaaland R, et al. Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer. PLoS One. 2013;8:e62153.CrossRefPubMedPubMedCentral
26.
go back to reference Ji HF, Pang D, Fu SB, Jin Y, Yao L, Qi JP, et al. Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer. J Cancer Res Clin Oncol. 2013;139:429–35.CrossRefPubMed Ji HF, Pang D, Fu SB, Jin Y, Yao L, Qi JP, et al. Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer. J Cancer Res Clin Oncol. 2013;139:429–35.CrossRefPubMed
Metadata
Title
Evaluation of new classifications of N descriptor in non-small cell lung cancer (NSCLC) based on the number and the ratio of metastatic lymph nodes
Authors
Konrad Pawełczyk
Marek Marciniak
Piotr Błasiak
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Cardiothoracic Surgery / Issue 1/2016
Electronic ISSN: 1749-8090
DOI
https://doi.org/10.1186/s13019-016-0456-5

Other articles of this Issue 1/2016

Journal of Cardiothoracic Surgery 1/2016 Go to the issue